The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Advances Day 2019 | Future therapies for MF: pacritinib, momelotinib, fedratinib & other pathways
Ruben Mesa
• 15 Nov 2019
Speaking at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Ruben Mesa, MD, FACP, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the latest treatments in development for myelofibrosis, as well as understanding of the disease. He highlights JAK inhibitors, as well as other pathway inhibitors such as LSD1, BET, MDM2 and TGF-β.
